Abstract
Mosaic chromosomal alterations of the autosomes (aut-mCAs) are large structural somatic mutations which cause clonal hematopoiesis and increase cancer risk. Here, we detected aut-mCAs in 1,011,269 participants across four biobanks. Through integrative analysis of the minimum critical region and inherited genetic variation, we found that proto-oncogenes exclusively drive chromosomal gains, tumor suppressors drive losses, and copy-neutral events can be driven by either. We identified three novel inherited risk loci in CHI3L2, HLA class II, and TERT that modulate aut-mCA risk and ten novel aut-mCA-specific loci. We found specific aut-mCAs are associated with cardiovascular, cerebrovascular, or kidney disease incidence. High-risk aut-mCAs were associated with elevated plasma protein levels of therapeutically actionable targets: NPM1, PARP1, and TACI. Participants with multiple high-risk features such as high clonal fraction, more than one aut-mCA, and abnormal red cell morphology had a 50% cumulative incidence of blood count abnormalities over 2 years. Leveraging inherited variation, we causally established aut-mCAs as premalignant lesions for chronic lymphocytic leukemia. Together, our findings provide a framework integrating somatic mosaicism, germline genetics, and clinical phenotypes to identify individuals who could benefit from preventative interventions.
Competing Interest Statement
A.G.B. has received honoraria for advisory board membership from, and holds equity in, TenSixteen Bio.
Funding Statement
This work was supported by National Institutes of Health grant R01AG083736 (A.G.B., P.L.A., P.S.), National Institutes of Health grant R01HL117626, National Institutes of Health contract HHSN268201800002I, National Institutes of Health grant R01HL120393, National Institutes of Health grant U01HL120393, National Institutes of Health contract HHSN268201800001I, National Institutes of Health grant DP5OD029586 (A.G.B.) and National Institutes of Health grant T32GM007347 (Y.P.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The genotypes and phenotypes of UKB and AoU participants are available by application to the UKB (https://www.ukbiobank.ac.uk/register- apply/) and AoU (https://allofus.nih.gov/), respectively. Instructions for access to UK Biobank data are available at https://www.ukbiobank.ac.uk/enable-your-research. The HapMap3 reference panel was downloaded from ftp://ftp.ncbi.nlm.nih. gov/hapmap/, GnomAD v3.1 VCFs were obtained from https://gnomad.broadinstitute.org/downloads, and mCA calls for TOPMED Freeze 8 were obtained from dbGaP as described in https://topmed.nhlbi.nih.gov/topmed-whole-genome-sequencing-methods-freeze-8.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos